BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$27.85 USD
+3.23 (13.12%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $27.78 -0.07 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
BridgeBio Pharma, Inc. [BBIO]
Reports for Purchase
Showing records 1 - 20 ( 38 total )
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
BBP-418 Pivotal Trial Surpasses Interim Analysis Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Key Takeaway From Biotech Breakthroughs ATTRCM Event Part 2
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Infigratinib Demonstrates Durability in Achondroplasia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Additional Acoramidis Pivotal Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Remains Compelling; Oncology Spinout; Modulating PT to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis European Rights Licensed to Bayer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Pipeline Advancing; 2023 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Infigratinib Partnered in Japan; TTR Amyloidosis Competition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Application Accepted for Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Notches Pivotal Trial Success in Japan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis FDA Decision in 4Q24; Pipeline Maturation; Raising PT to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Optimized Entry and Exit Levels for BBIO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
E.N.D.O - Exploring New Drug Opportunities in Endocrinology KOL Call Highlights
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Updated Acoramidis Data; Outlook Remains Speculative; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Novel Compounds to Treat ATTR Amyloidosis Appear on Track to Generate Peak Annual Revenues of $50B-Plus
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
BBP-418 Proof-of-Concept Data; NULIBRY Asset Sale; Adjusting PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Multiple Pipeline Catalysts Approaching; 2021 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Second Gene Therapy Candidate Enters Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Precision Oncology Collaboration With Amgen Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Phase 3 Trial Misses Primary Endpoint; Lowering PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R